Nevin Murray
Overview
Explore the profile of Nevin Murray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, et al.
Lung Cancer
. 2019 Jun;
133:48-55.
PMID: 31200828
Introduction: Activation of the RAS/RAF/MEK/ERK pathway may confer resistance to chemotherapy in non-small cell lung cancer (NSCLC). Selumetinib (AZD6244, ARRY142886), a MEK1/2 inhibitor combined with chemotherapy in patients with NSCLC...
2.
Leighl N, Tsao M, Liu G, Tu D, Ho C, Shepherd F, et al.
Oncotarget
. 2017 Oct;
8(41):69651-69662.
PMID: 29050231
Purpose: MET and AXL mediate resistance to EGFR TKI in NSCLC. Foretinib, a MET/RON/AXL/TIE-2/VEGFR kinase inhibitor may overcome EGFR kinase resistance. This dose escalation study combined foretinib and erlotinib in...
3.
Rodda S, Tyldesley S, Morris W, Keyes M, Halperin R, Pai H, et al.
Int J Radiat Oncol Biol Phys
. 2017 Apr;
98(2):286-295.
PMID: 28433432
Purpose: To report the genitourinary (GU) and gastrointestinal (GI) morbidity and erectile dysfunction in a randomized trial comparing 2 methods of dose escalation for high- and intermediate-risk prostate cancer. Methods...
4.
Morris W, Tyldesley S, Rodda S, Halperin R, Pai H, Mckenzie M, et al.
Int J Radiat Oncol Biol Phys
. 2017 Mar;
98(2):275-285.
PMID: 28262473
Purpose: To report the primary endpoint of biochemical progression-free survival (b-PFS) and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 methods of dose escalation for intermediate- and high-risk...
5.
Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, et al.
J Thorac Oncol
. 2016 Jul;
11(11):2018-2021.
PMID: 27449804
There is no approved second-line systemic therapy option for malignant pleural mesothelioma (MPM), but targeting angiogenesis is an area of investigation. PF-03446962 is a fully human antibody against activin receptor-like...
6.
7.
Melosky B, Anderson H, Burkes R, Chu Q, Hao D, Ho V, et al.
J Clin Oncol
. 2015 Nov;
34(8):810-5.
PMID: 26573073
Purpose: Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with advanced non-small-cell lung cancer (NSCLC) whose epidermal growth factor receptor expression status is positive or unknown. Although...
8.
Noonan K, Ho C, Laskin J, Murray N
J Thorac Oncol
. 2015 Nov;
10(11):1523-31.
PMID: 26536194
Over the past three decades, survival in advanced non-small-cell lung cancer (NSCLC) clinical trials has doubled with an increase in 1-year survival from 25% to 50 to 55%. This has...
9.
10.
Richter S, Seah J, Pond G, Gan H, MacKenzie M, Hotte S, et al.
Can Urol Assoc J
. 2015 Jan;
8(11-12):398-402.
PMID: 25553152
Introduction: Pivotal phase III trials have positioned angiogenesis inhibitors as first-line therapy for the management of most advanced or metastatic renal cell carcinomas (mRCC). Approaches to second-line therapy, however, remain...